Etamsylate

Chemical formula: C₁₀H₁₇NO₅S  Molecular mass: 263.31 g/mol 

Pregnancy

There are limited amount of data from the use of etamsylate in pregnant women. Animal experiments have not revealed any direct or indirect toxicity affecting pregnancy, embryonic development, foetal development and/or post-natal development. As a precautionary measure, it is preferable to avoid the use of etamsylate during pregnancy.

Nursing mothers

In the absence of data concerning passage into breast milk, breast-feeding is inadvisable during treatment. Alternatively, the treatment should be stopped if breast-feeding is continued.

Effects on ability to drive and use machines

Etamsylate has no effect upon driving capacity and managing of machines.

Adverse reactions


The side effects are classified according to the MedDRA convention by system organ class and by frequency as follows: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1 000 to <1/100), Rare (≥1/10 000 to <1/1 000), Very rare (<1/10 000), not known (cannot be estimated from the available data).

Oral administration:

Gastrointestinal disorders

Common: nausea, diarrhoea, gastralgia, abdominal discomfort.

Skin and subcutaneous tissue disorders

Common: rash.

General disorders and administration site conditions

Common: asthenia

Very rare: fever.

Nervous System disorders

Common: headache.

Vascular disorders

Very rare: thromboembolism.

Blood and lymphatic system disorders

Very rare: agranulocytosis, neutropenia, thrombocytopenia.

Musculoskeletal and connective tissue disorders

Rare: arthralgia.

Immune System Disorders

Very rare: hypersensitivity.

IV / IM administration:

Gastrointestinal disorders

Common: nausea, abdominal discomfort.

Skin and subcutaneous tissue disorders

Common: rash.

General disorders and administration site conditions

Common: asthenia.

Very rare: fever.

Nervous System disorders

Common: headache.

Vascular disorders

Very rare: thromboembolism, hypotension.

Blood and lymphatic system disorders

Very rare: agranulocytosis, neutropenia, thrombocytopenia.

Musculoskeletal and connective tissue disorders

Rare: arthralgia.

Immune System Disorders

Very rare: hypersensitivity.

These reactions are generally reversible when stopping treatment course. In case of skin reactions or fever, the treatment must be stopped and the treating physician informed as this may constitute hypersensitivity reactions.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.